COMMUNIQUÉS West-GlobeNewswire

-
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 13 mars 2024
20/03/2024 -
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
20/03/2024 -
PHAXIAM Therapeutics publie ses résultats annuels 2023 et fait le point sur ses activités
20/03/2024 -
Zealand Pharma's Annual General Meeting 2024
20/03/2024 -
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20/03/2024 -
DAS Health Expands Presence with New Chicago Office Location
20/03/2024 -
SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND PROVIDES TRADING UPDATE
20/03/2024 -
Orion Corporation: Organising meeting of the Board of Directors
20/03/2024 -
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
20/03/2024 -
COVID Origin Is a Gordian Knot, according to the Journal of American Physicians and Surgeons
20/03/2024 -
Decisions taken by Orion Corporation’s Annual General Meeting on 20 March 2024
20/03/2024 -
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20/03/2024 -
XTL To Aquire The Social Proxy
20/03/2024 -
Dr. Zeke Unveils Breakthrough Scoliosis Treatment, Transforming Lives in Austin, TX
20/03/2024 -
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
20/03/2024 -
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
20/03/2024 -
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
20/03/2024 -
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
20/03/2024 -
TFF Pharmaceuticals Announces Update on Clinical Programs
20/03/2024
Pages